Reata Pharmaceuticals, Inc. - (RETA) Social Stream
REATA PHARMACEUTICALS INC (RETA) Price Targets From Analysts
Use the tables below to see what analysts covering REATA PHARMACEUTICALS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 8 | $282 | $155 | $220.25 | $41.61 | 429.32% |
| 2021-12-07 | 7 | $282 | $112 | $205.875 | $41.61 | 394.77% |
| 2021-12-09 | 8 | $244 | $35 | $94.625 | $41.61 | 127.41% |
| 2022-03-01 | 8 | $244 | $35 | $80.625 | $41.61 | 93.76% |
| 2022-03-02 | 8 | $244 | $35 | $80.875 | $41.61 | 94.36% |
| 2022-05-04 | 6 | $244 | $35 | $80.875 | $41.61 | 94.36% |
| 2022-05-11 | 7 | $244 | $35 | $80.875 | $41.61 | 94.36% |
| 2022-05-24 | 7 | $75 | $35 | $58.5 | $41.61 | 40.59% |
| 2022-08-09 | 8 | $75 | $35 | $57.111 | $41.61 | 37.25% |
| 2022-08-11 | 8 | $75 | $27 | $51 | $41.61 | 22.57% |
| 2022-10-11 | 8 | $75 | $27 | $51.222 | $41.61 | 23.1% |
| 2022-10-19 | 9 | $75 | $27 | $53.6 | $41.61 | 28.82% |
| 2022-11-08 | 10 | $75 | $27 | $53.6 | $41.61 | 28.82% |
| 2022-11-09 | 10 | $86 | $27 | $56.2 | $41.61 | 35.06% |
| 2022-11-28 | 10 | $115 | $27 | $61.1 | $41.61 | 46.84% |
The Trend in the Analyst Price Target
Over the past 22 months, RETA's average price target has gone down $185.65.
RETA reports an average of 141.29% for its upside potential over the past 39 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-05-04 | 6 | 244 | 35 | 80.875 | 27.00 | 199.54% |
| 2022-05-11 | 7 | 244 | 35 | 81.111 | 22.71 | 257.16% |
| 2022-08-11 | 8 | 75 | 27 | 51.000 | 20.96 | 143.32% |
| 2022-11-08 | 10 | 75 | 27 | 53.600 | 40.29 | 33.04% |
| 2022-11-09 | 10 | 86 | 27 | 56.800 | 38.27 | 48.42% |
RETA Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.4 | 8 | 0 | 2 | 0 | 0 | 10 |
The Trend in the Broker Recommendations
RETA's average broker recommendation rating improved by 0.1 over the prior 35 weeks.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, REATA PHARMACEUTICALS INC's variance in analysts' estimates is lower than -1888.06% of them.
- RETA has a higher average analyst price target than 1807.07% of Pharmaceutical Products stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, REATA PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is greater than 795.74% of them.
- In terms of how REATA PHARMACEUTICALS INC fares relative to Pharmaceutical Products stocks, note that its number of analysts covering the stock is greater than 1479.5% of that group.
Stocks similar to REATA PHARMACEUTICALS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are AXSM, BPMC, and MCRB.
View All Top Stocks by Price Target
What is the outlook for RETA? Use POWR Ratings for clearer insight into price direction.